$110,000 The ASF Joseph Wagstaff Postdoctoral Research Fellowship was granted to its first recipient. Dr. King will do his postdoctoral research on a new drug UNCilencer1, which turns on the silenced paternal UBE3A gene in mouse neurons. UNCilencer1 is a […]
Read more
$200,000 (2-year award) Dr. Peter Howley, a long-time investigator into the role of UBE3A, has been funded by ASF to conduct state-of-the-art studies that have promise for identifying new protein targets and interacting proteins for UBE3A. This work involves using […]
Read more
$197,580 (2-year award) This project enabled Dr. Klann to continue his studies on the synapse and on the action of an important group of proteins, the neuregulins. At the neuronal cell membrane, these proteins are known to interact with an […]
Read more
$198,899 (2-year award) As research improves our understanding of synapse function in normal individuals and how it is abnormal in those with AS, we are approaching an exciting time when therapeutic drug agents or chemicals can be tested in the […]
Read more
$199,972 (2-year award) Funding for this grant is an attempt to promote research targeted to identifying agents or druggable compounds that may increase expression of UBE3A in brain neurons. Using multidisciplinary facilities, advanced genetic engineering and robotic drug analysis, this grant […]
Read more$25,000 – RDCRN Training Grant This proposal seeks to compare the yield of routine EEGs obtained as a standard in the Angelman Natural History protocol with two other types of EEG recordings to identify common EEG patterns. These patterns include […]
Read more